BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...SURF4 - Surfeit 4STK25 - Schistosoma mansoni Serine/threonine kinase 25...
BioCentury | Oct 28, 2020
Distillery Therapeutics

STK25 and TAO1 identified as schistosomiasis targets

...By Claire Quang, Staff Writer  DISEASE CATEGORY: Infectious diseaseINDICATION: InfectiousInhibiting the serine/threonine kinases STK25 and TAO1...
...in parasite attachment or stem cell maintenance, including STK25 and TAO1. In vitro, RNAi of STK25...
...infected with untreated parasites, suggesting that STK25 and TAO1 depletion reduces parasite survival. TARGET/MARKER/PATHWAY: Schistosoma mansoni Serine/threonine kinase 25 (STK25); Schistosoma...
BioCentury | Aug 2, 2012
Distillery Therapeutics

Indication: Cancer

...studies suggest increasing STK25 activity could help treat pediatric neural cancers. In human embryonic fibroblasts, STK25-targeting...
...RNA decreased CCM2-dependent cell death compared with control shRNA. In 478 patients with neuroblastoma, high STK25...
...overall survival. Next steps include identifying small molecules that affect the expression or interactions of STK25...
Items per page:
1 - 3 of 3